Cargando…
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
Adoptive T-cell immunotherapies, including chimeric antigen receptor-modified T-cells (CAR-T cells), have revolutionized cancer treatment, especially for hematologic malignancies. Clinical success of CAR-T cell monotherapy in solid tumors however, has been only modest. Oncolytic viruses provide dire...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160535/ https://www.ncbi.nlm.nih.gov/pubmed/30298067 http://dx.doi.org/10.3389/fimmu.2018.02103 |
_version_ | 1783358785699446784 |
---|---|
author | Rosewell Shaw, Amanda Suzuki, Masataka |
author_facet | Rosewell Shaw, Amanda Suzuki, Masataka |
author_sort | Rosewell Shaw, Amanda |
collection | PubMed |
description | Adoptive T-cell immunotherapies, including chimeric antigen receptor-modified T-cells (CAR-T cells), have revolutionized cancer treatment, especially for hematologic malignancies. Clinical success of CAR-T cell monotherapy in solid tumors however, has been only modest. Oncolytic viruses provide direct cancer cell lysis, stimulate systemic immune responses, and have the capacity to provide therapeutic transgenes. Oncolytic virotherapy has shown great promise in many preclinical solid tumor models and the first oncolytic virus has been approved by the FDA for the treatment of advanced melanoma. As monotherapies for solid tumors, oncolytic virotherapy provides only moderate anti-tumor effects. However, due to their complementary modes of action, oncolytic virus and T-cell therapies can be combined to overcome the inherent limitations of each agent. This review focuses on the aspects of oncolytic viruses that enable them to synergize with adoptive T-cell immunotherapies to enhance anti-tumor effects for solid tumors. |
format | Online Article Text |
id | pubmed-6160535 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61605352018-10-08 Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment Rosewell Shaw, Amanda Suzuki, Masataka Front Immunol Immunology Adoptive T-cell immunotherapies, including chimeric antigen receptor-modified T-cells (CAR-T cells), have revolutionized cancer treatment, especially for hematologic malignancies. Clinical success of CAR-T cell monotherapy in solid tumors however, has been only modest. Oncolytic viruses provide direct cancer cell lysis, stimulate systemic immune responses, and have the capacity to provide therapeutic transgenes. Oncolytic virotherapy has shown great promise in many preclinical solid tumor models and the first oncolytic virus has been approved by the FDA for the treatment of advanced melanoma. As monotherapies for solid tumors, oncolytic virotherapy provides only moderate anti-tumor effects. However, due to their complementary modes of action, oncolytic virus and T-cell therapies can be combined to overcome the inherent limitations of each agent. This review focuses on the aspects of oncolytic viruses that enable them to synergize with adoptive T-cell immunotherapies to enhance anti-tumor effects for solid tumors. Frontiers Media S.A. 2018-09-21 /pmc/articles/PMC6160535/ /pubmed/30298067 http://dx.doi.org/10.3389/fimmu.2018.02103 Text en Copyright © 2018 Rosewell Shaw and Suzuki. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Rosewell Shaw, Amanda Suzuki, Masataka Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment |
title | Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment |
title_full | Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment |
title_fullStr | Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment |
title_full_unstemmed | Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment |
title_short | Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment |
title_sort | oncolytic viruses partner with t-cell therapy for solid tumor treatment |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160535/ https://www.ncbi.nlm.nih.gov/pubmed/30298067 http://dx.doi.org/10.3389/fimmu.2018.02103 |
work_keys_str_mv | AT rosewellshawamanda oncolyticvirusespartnerwithtcelltherapyforsolidtumortreatment AT suzukimasataka oncolyticvirusespartnerwithtcelltherapyforsolidtumortreatment |